CTOs on the Move

HealthTell

www.healthtell.com

 
HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.healthtell.com
  • 3130 Crow Canyon Place Suite 210
    San Ramon, CA USA 94583
  • Phone: 925.361.3115

Executives

Name Title Contact Details

Similar Companies

Quellis Biosciences

Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.

Tekmira Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aastrom

We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.

BioHouston Inc

BioHouston Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entasis

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Our deep pipeline of novel clinical and preclinical antibacterial programs is designed to revolutionize the way physicians treat serious bacterial diseases.